Retrospective study of unresectable stage III or stage IV melanoma refractory to immune checkpoint and BRAF/MEK inhibitors, treated with triplet vs doublet therapy: A single institution experience

Authors

Hariharasudan Mani MD, Lehigh Valley Health NetworkFollow
Nicole Nester DO, Lehigh Valley Health NetworkFollow
Grace Rauscher
Timothy Johnson MD, Lehigh Valley Health NetworkFollow
Zeeshan Hafeez MD, Lehigh Valley Health NetworkFollow
Darshan Lal MD, Lehigh Valley Health NetworkFollow
Colby L. Presley, Lehigh Valley Health NetworkFollow
Hope Kincaid MPH, CPH, Lehigh Valley Health NetworkFollow
Alyson McIntosh MD, Lehigh Valley Health NetworkFollow
Aaron U. Blackham MD, Lehigh Valley Health NetworkFollow
Suresh G. Nair MD, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

5-2025

Volume

43

Issue

16

Published In/Presented At

https://doi.org/10.1200/JCO.2025.43.16_suppl.e2150

Disciplines

Medicine and Health Sciences

Department(s)

Department of Medicine, Hematology-Medical Oncology Division Fellows and Residents, Hematology-Medical Oncology Division, Fellows and Residents, Department of Surgery, Network Office of Research and Innovation, Department of Radiation Oncology

Document Type

Article